Saturday, April 30th, 2016 - RnR Market Research

Global Markets Direct's, Anxiety Disorders - Pipeline Review, H1 2016 report provides an overview of the Anxiety Disorders pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anxiety Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anxiety Disorders and features dormant and discontinued projects.

To buy complete report on Anxiety Disorders pipeline Review, H1 2016 with 7 market data tables and 9 figures, spread across 284 pages -

Companies Discussed in this report are – AbbVie Inc.Ache Laboratorios Farmaceuticos S/A , Adamed Sp. z o.o. , Addex Therapeutics Ltd , morsa Therapeutics Inc., Avineuro Pharmaceuticals, Inc.,  Azevan Pharmaceuticals, Inc. , Bionomics Limited , Boehringer Ingelheim GmbH , C4X Discovery Holdings PLC , Catalyst Pharmaceutical Partners, Inc. , Edgemont Pharmaceuticals, LLC , Eisai Co., Ltd. , Eli Lilly and Company, F. Hoffmann-La Roche Ltd.  ,Gabather AB , GW Pharmaceuticals Plc , HolsboerMaschmeyer NeuroChemie GmbH , Humanetics Corporation , IntelGenx Corp. , Intra-Cellular Therapies, Inc. , INVENT Pharmaceuticals, Inc., Marinus Pharmaceuticals, Inc. , Merz Pharma GmbH & Co. KgaA , MI.TO. Technology S.r.L. , Nemus ioscience, Inc., Neuralstem, Inc., Neurelis, Inc. , NeuroNascent, Inc. , Newron Pharmaceuticals S.p.A. , Nippon Chemiphar Co., Ltd. , Novartis AG,  Omeros Corporation , Otsuka Holdings Co., Ltd. , Pherin Pharmaceuticals, Inc. , Polleo Pharma Limited , Protagenic Therapeutics Inc. , Suda Ltd , Sumitomo Dainippon Pharma Co., Ltd. , Synchroneuron Inc, Tonix Pharmaceuticals Holding Corp. , Trevena, Inc., TRImaran Pharma, Inc., Turing Pharmaceuticals AG, Vanda Pharmaceuticals Inc.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

For Discount on this report -  


  • The report provides a snapshot of the global therapeutic landscape of Anxiety Disorders
  • The report reviews pipeline therapeutics for Anxiety Disorders by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Anxiety Disorders therapeutics and enlists all their major and minor projects
  • The report assesses Anxiety Disorders therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Anxiety Disorders

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Anxiety Disorders
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Anxiety Disorders pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

File Library

Contact Profile

RnR Market Research

About Us: is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us: 

G+ / Google Plus:



RSS / Feeds:

Ritesh Tiwari
P: + 1 888 391 5441


Anxiety Disorders Market, Anxiety Disorders Pipeline, Anxiety Disorders Market 2016, Anxiety Disorders Therapeutics




More Formats